For the 2017-18 flu season, the U.S. Centers for Disease Control and Prevention endorsed only three antiviral drugs for treating flu. Unlike those treatments, the compound baloxavir inhibits the virus’s machinery for making genetic information that it needs to replicate itself. Frederick Hayden at the UVA School of Medicine and his colleagues performed two clinical trials of baloxavir in people with flu.